S2Medical AB Class B (S2M) AI Stock Analysis

• Market Cap: €11.40M
• Dividend Yield: N/A
• Average Volume (3M): 11.21M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: 96.10%
• EPS Growth: 94.79%
• Country: SE
• Employees: 17
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 836,139,600
• 10 Day Avg. Volume: 6,955,916
• 30 Day Avg. Volume: 11,214,555
• PEG Ratio: -0.04
• Price to Book (P/B): 5.11
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 61 Neutral
• Price Target: ―

S2Medical AB Class B demonstrates strong financial performance with significant revenue and profit growth, positive cash flow, and a stable balance sheet. However, technical indicators show moderate momentum, and the negative P/E ratio raises valuation concerns. The overall score reflects a promising financial outlook but tempered by valuation and historical volatility risks.

S2Medical AB Class B Business Overview & Revenue Model

Company Description

S2Medical AB Class B (S2M) is a Swedish medical technology company specializing in the development and commercialization of advanced wound care products. The company operates within the healthcare sector, focusing on innovative solutions for wound healing and tissue regeneration. Its core products include a range of patented wound care technologies designed to improve healing outcomes and reduce the risk of infections.

How the Company Makes Money

S2Medical AB generates revenue primarily through the sale of its advanced wound care products to hospitals, clinics, and other healthcare providers. The company's revenue model is based on direct sales, as well as partnerships and distribution agreements with medical distributors and healthcare organizations across various regions. Significant factors contributing to its earnings include the efficacy of its patented technologies, ongoing research and development efforts, and strategic collaborations with healthcare providers to expand product reach and adoption in different markets.

S2Medical AB Class B Financial Statement Overview

Summary

S2Medical AB Class B has shown strong revenue growth of 113.9% and improved profit margins. The balance sheet is stable with zero debt and a strong equity position. Cash flow management is robust, with positive free cash flow. However, historical volatility and a modest asset base present potential risks.

Income Statement

S2Medical AB Class B has shown a significant improvement in its financial performance over the past year. The company reported a substantial increase in total revenue from SEK 6.97 million in 2023 to SEK 14.91 million in 2024, reflecting a revenue growth rate of 113.9%. Gross profit margin is strong at 94.9%, indicating effective cost management. The net profit margin turned positive at 38.7% in 2024, compared to a negative margin in previous years, showing a successful turnaround. EBITDA margin has improved significantly to 45.8%. However, the historical volatility in earnings and previous losses suggest potential risks.

Balance Sheet

The company's balance sheet reflects a strong equity position with a total debt of zero and stockholders' equity amounting to SEK 11.8 million in 2024. The equity ratio is 65.2%, indicating financial stability and low leverage. Return on equity (ROE) has improved to 48.9%, demonstrating efficient use of equity capital. While the absence of debt is a positive indicator, the relatively modest asset base may limit growth opportunities compared to industry peers with larger asset pools.

Cash Flow

S2Medical AB Class B has demonstrated robust cash flow management. The free cash flow turned positive at SEK 2.49 million in 2024, reflecting significant improvement from previous negative figures. The operating cash flow to net income ratio is favorable at 0.54, indicating efficient cash conversion from profits. Additionally, the free cash flow to net income ratio suggests strong cash generation relative to earnings. The positive cash flow trajectory is a promising sign for sustaining future operations and investments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.57M	14.91M	6.97M	4.67M	7.70M	25.62M
Gross Profit	-2.78M	14.14M	5.04M	5.17M	7.10M	10.05M
EBITDA	3.92M	6.82M	-13.53M	-26.37M	-18.73M	-14.14M
Net Income	-2.15M	5.77M	-22.71M	-31.22M	-20.32M	-15.08M
Balance Sheet
Total Assets	17.62M	18.09M	21.41M	25.29M	29.68M	41.24M
Cash, Cash Equivalents and Short-Term Investments	1.37M	1.00M	1.52M	3.72M	9.48M	25.14M
Total Debt	0.00	0.00	0.00	0.00	207.69K	830.77K
Total Liabilities	7.48M	6.29M	19.75M	18.22M	15.00M	8.48M
Stockholders Equity	10.14M	11.80M	1.66M	7.07M	14.68M	32.77M
Cash Flow
Free Cash Flow	13.31M	2.49M	-17.67M	-30.03M	-22.76M	-14.73M
Operating Cash Flow	14.45M	3.12M	-16.52M	-28.13M	-19.67M	-12.75M
Investing Cash Flow	-1.14M	-634.00K	-1.15M	-1.76M	-3.02M	-1.98M
Financing Cash Flow	-13.60M	3.79M	15.47M	24.14M	6.85M	24.41M

S2Medical AB Class B Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:S2M, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.09 is Neutral, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:S2M.

S2Medical AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
S2M	61 Neutral	€11.40M	―		―	96.10%	94.79%
Sector *	51 Neutral	kr5.56B	11.18	-74.16%	8.44%	28.10%	22.23%
CLS.B	47 Neutral	kr81.88M	―	-79.12%	―	86.02%	93.34%
CLS.B	47 Neutral	kr81.88M	―	-79.12%	―	86.02%	93.34%
ACARIX	46 Neutral	kr367.52M	―	-88.97%	―	-0.61%	54.19%
HEART	34 Underperform	€68.48M	―		―	―	―
QLIFE	33 Underperform	kr62.17M	―		―	-63.52%	93.00%